Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,623 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05010005RecruitingPhase 1
Testing ruxolitinib plus duvelisib for relapsed T-cell lymphoma
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
Miami, FloridaAges 18 years+ - NCT05010122RecruitingPhase 1/Phase 2
Testing venetoclax and gilteritinib with ASTX727 for FLT3 leukemia
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
Houston, TexasAges 18 years+ - NCT05010681RecruitingPhase 2
Lenvatinib plus immunotherapy after prior liver cancer treatment
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05012111Recruiting
Study of bone marrow failure causes over time
This study looks at the natural history (how a condition progresses) in people with acquired or inherited bone marrow failure syndromes, including related lung and liver findings in some cases. It helps researchers understand underlying causes—sometimes linked to gene or telomere changes—and how symptoms evolve, which may guide future care.
Bethesda, MarylandAges 2–99 - NCT05019703RecruitingPhase 2
Atezolizumab plus cabozantinib for teen osteosarcoma
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
Boston, MassachusettsAges 12 years+ - NCT05026983RecruitingPhase 2
Targeted drugs for melanoma spread to the brain
This Phase 2 trial tests two targeted medicines (binimetinib and encorafenib) for melanoma that has spread to the brain. It focuses on people whose tumor has a specific BRAF V600 mutation and who have brain metastases that are progressing or need treatment.
Houston, TexasAges 18 years+ - NCT05025813RecruitingPhase 2
Pembrolizumab before surgery or radiation for high-risk skin SCC
This Phase 2 trial tests pembrolizumab (an immune therapy) given before surgery to see if it can help control high-risk invasive cutaneous squamous cell carcinoma. The goal is to improve outcomes by treating cancer earlier and then following with standard surgery and radiation if needed.
Camperdown, New South WalesAges 18 years+ - NCT05030597Recruiting
PET scans targeting FAP for oral cancer and recurrence
This trial uses a special PET scan that targets a substance called FAP to better find oral squamous cell cancer and check for recurrence. It may help doctors see where cancer activity is and guide treatment planning, especially around surgery and (for some people) neoadjuvant therapy before surgery.
Wuhan, HubeiAges 18–70 - NCT05033392RecruitingPhase 2
PD-1 therapy plus chemotherapy before stomach cancer surgery
This Phase 2 trial tests whether adding a PD-1 antibody (JS001/toripalimab) to chemotherapy before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction adenocarcinoma. It aims to help shrink the tumor and make surgery more effective.
Shenzhen, GuangdongAges 18–79 - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT05048212RecruitingPhase 2
Nivolumab, ipilimumab, and cabozantinib for kidney cancer brain spread
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
Houston, TexasAges 18 years+ - NCT05049317Recruiting
Check urinary and sexual function after rectal cancer surgery
This study looks at how a specific rectal surgery (laparoscopic total mesorectum excision) affects urinary and sexual function after the operation. It may help patients by tracking what to expect and which factors relate to better recovery.
Wuhan, HubeiAges 18–70 - NCT05053854RecruitingPhase 1
Testing a PARP drug plus targeted radiation for bowel or pancreas tumors
This Phase 1 study tests how safe and effective it is to combine a PARP inhibitor (a targeted cancer medicine) with PRRT, a treatment that delivers radiation directly to certain tumor cells. It is for people with grade 2 neuroendocrine tumors from the pancreas or intestines, especially when scans suggest the tumor will take up the targeted radiation.
Melbourne, VictoriaAges 18 years+ - NCT05055063RecruitingPhase 1
Belantamab for high-risk smoldering myeloma safety and early benefit
This Phase 1 trial tests belantamab mafodotin, a cancer medicine, in people with high-risk smoldering multiple myeloma to see how safe it is and whether it may shrink or control the disease. Because it’s an early-stage study, you would be closely monitored and treated with one main study drug.
Houston, TexasAges 18 years+ - NCT05064280RecruitingPhase 2
Pembrolizumab plus lenvatinib for brain metastases from solid tumors
This Phase 2 trial studies whether combining pembrolizumab with lenvatinib can shrink or control brain metastases in people with triple-negative breast cancer, lung cancer, or other solid tumors. It focuses on patients who have measurable brain lesions that can be followed on MRI.
Houston, TexasAges 18 years+ - NCT05076500Recruiting
How radiotherapy changes a tumor’s immune response
This study looks at how a tumor’s immune system responds when you receive radiotherapy. It involves taking a planned pre-treatment biopsy so researchers can study immune and tumor changes and see if radiotherapy affects them.
ManchesterAges 18 years+ - NCT05083754RecruitingPhase 1
New glioblastoma trial testing immune drug plus radiation
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
Baltimore, MarylandAges 18–100 - NCT05097625Recruiting
Testing early detection of head and neck cancer relapse
This study aims to find signs of head and neck cancer coming back early, using scans/tests after you’ve had radical treatment. If you’re at higher risk and HPV-negative, this may help doctors catch relapse sooner.
LondonAges 18 years+ - NCT05100095RecruitingPhase 2
Radiation schedule study for Merkel cell skin cancer
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
Houston, TexasAges 18 years+ - NCT05106296RecruitingPhase 1
Chemo-immunotherapy with ibrutinib and indoximod for pediatric brain tumors
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
Augusta, GeorgiaAges 3–25 - NCT05123625Recruiting
Testing lymph node removal during bladder cancer surgery
This study looks at whether removing nearby lymph nodes during radical cystectomy (bladder removal) improves outcomes for people with high-risk non–muscle-invasive bladder cancer. It may help doctors choose the best surgical approach to reduce the chance of cancer coming back.
Nanjing, JiangsuAges 18–75 - NCT05126160Recruiting
MRI-based imaging to guide treatment in nasopharyngeal cancer
This study uses special MRI images (and computer “radiomics” scores) to better understand nasopharyngeal cancer. The goal is to help doctors choose the most appropriate treatment for people with newly diagnosed cancer.
Wuhan, HubeiAges 18–70 - NCT05132504RecruitingPhase 2
Pre-surgery chemotherapy and immunotherapy for operable pancreatic cancer
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Houston, TexasAges 18 years+ - NCT05141253RecruitingEarly Phase 1
Trial of RD133 for mesothelin-positive tumors after prior treatment
This early-stage trial tests whether RD133 can be safe and effective for people whose solid tumors have a high “mesothelin” marker and that have not responded to at least two standard treatments. If you qualify, you’ll be checked closely for side effects and whether the tumor responds.
Wuhan, HubeiAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,623 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.